Zydus Lifesciences Limited (including its subsidiaries, hereafter referred to as "Zydus"), an innovation-led global lifesciences company, has launched Semaglutide Injection under the brand names - ...
Zydus Lifesciences has launched Semaglutide Injection under the brand names SEMAGLYN, MASHEMA and ALTERME, upon patent expiry in India. The Drug Controller General of India (DCGI) had earlier provided ...
Rising Chronic Disease Burden, Biosimilar Insulin Adoption, and Smart Connected Pen Technologies Drive Sustained Market Expansion.Austin, United States, March 12, 2026 (GLOBE NEWSWIRE) -- As per SNS ...
A real-world study conducted across 9 European countries found that bolus injection frequency and engagement with a smart pen to administer insulin were associated with improved glycemic control among ...
Zydus Lifesciences Limited has launched Semaglutide Injection in India under the brand names SEMAGLYN, MASHEMA, and ALTERME ...
The global injection pen market is set to witness a growth rate of 7% in the next 5 years. Rising prevalence of chronic diseases, patient convenience and ease of use, technological advancements, ...
For people who require insulin therapy, staying on top of multiple daily injections and getting the dosages right can be an overwhelming task. Insulin pens can make diabetes management easier, and ...
Owen Mumford has released a new injection pen training video. Developed in collaboration with consultant pharmacists and nursing professionals, the video addresses critical steps when clinically ...
Anavip contains venom-specific F(ab’)2 fragments of immunoglobulin G that bind and neutralize venom toxins. Novo Nordisk announced the availability of Ozempic (semaglutide) injection 1mg as a single ...
Dublin, Nov. 05, 2020 (GLOBE NEWSWIRE) -- The "Injection Pen Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results